Pacira BioSciences, Inc. 10-Q

Item 5. OTHER INFORMATION Rule 10b5-1 Trading Plans The following table shows the “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted by our directors and executive officers during the quarter ended March 31, 2024. No trading arrangements were terminated by our directors and executive officers during the quarter ended March 31, 2024. Trading Arrangement Name and Position Action Date Rule 10b5-1* Non-Rule 10b5-1** Total Number of Shares to be Sold Expiration Date Lauren Riker Principal Accounting Officer Adopt 3/5/2024 x To Be Determined (1) 12/31/2024 Kristen Williams Chief Administrative Officer and Secretary Adopt 3/8/2024 x To Be Determined (1) 6/28/2024 Jonathan Slonin Chief Medical Officer Adopt 3/8/2024 x To Be Determined (1) 1/31/2025 Paul Hastings Director Adopt 3/12/2024 x 1,775 12/31/2024 Daryl Gaugler Chief Operating Officer Adopt 3/12/2024 x 2,500 3/7/2025 * Intended to satisfy the affirmative defense of Rule 10b5-1(c). ** Not intended to satisfy the affirmative defense of Rule 10b5-1(c). (1) The aggregate number of shares to be sold pursuant to each trading arrangement listed above is dependent on the amount of tax withholding required upon the vesting of restricted stock units, and, therefore, is indeterminable at this time. Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 45 Table of Contents Item 6. EXHIBITS The exhibits listed below are filed or furnished as part of this report. Exhibit Number Description 10.1 Executive Employment Agreement, dated May 4, 2020, between the Registrant and Jonathan Slonin.(1) *** 31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.* 31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.* 32.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.** 101 The following materials from the Quarterly Report on Form 10-Q of Pacira BioSciences, Inc. for the quarter ended March 31, 2024, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss); (iv) the Condensed Consolidated Statements of Stockholders’ Equity; (v) the Condensed Consolidated Statements of Cash Flows; and (vi) the Condensed Notes to Consolidated Financial Statements.* 104 Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101). * Filed herewith. ** Furnished herewith. *** Denotes management contract or compensatory plan or arrangement. (1) Incorporated by reference to the Company’s Quarterly Report on Form 10-Q, filed on May 4, 2022. Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 46 Table of Contents SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PACIRA BIOSCIENCES, INC. (REGISTRANT) Date: May 7, 2024 By: /s/ FRANK D. LEE Frank D. Lee Chief Executive Officer and Director (Principal Executive Officer) Date: May 7, 2024 By: /s/ CHARLES A. REINHART, III Charles A. Reinhart, III Chief Financial Officer (Principal Financial Officer) Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 47